
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics Inc. has reported a significant increase in operating expenses, rising 52% year-over-year to $7 million in Q2 FY25, highlighting substantial investment in growth and innovation. The company is transitioning to a new business model that promises to enhance revenue potential by 4-6 times per case while providing access to a larger patient base and maintaining healthy profit margins. Moreover, following successful pilot results with Rebis Health, Vivos is actively seeking partnerships and acquisitions with sleep test centers, indicating strong strategic growth initiatives in the market for sleep-disordered breathing solutions.
Bears say
Vivos Therapeutics Inc. reported revenues of $3.8 million for Q2 FY25, which fell short of the estimated $4.2 million and reflected a 6% year-over-year decline despite a 27% quarter-over-quarter increase. The company has revised its FY25 earnings per share (EPS) estimates down to $(2.13) from $(1.54) due to rising operating expenses, contributing to a pro forma EPS of $(0.55) that also missed prior expectations. Additionally, the company faces risks related to low visibility in financial performance and the potential for further dilution from financing activities.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares